Inspra (Eplerenone)

Eplerenone selectively antagonises the mineralocorticoid (aldosterone) receptor in the kidneys. This blocks aldosterone‑driven sodium and water reabsorption, leading to increased urinary excretion of sodium, reduced extracellular fluid volume, and consequently lower blood pressure and less cardiac strain.

The appropriate eplerenone dose is determined by the prescribing clinician based on the individual’s medical condition, renal function, and serum potassium levels. Dosage may be adjusted during therapy, and patients should follow the specific instructions provided by their healthcare professional.

Safety data for eplerenone in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Inspra, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to eplerenone is spironolactone, another mineralocorticoid receptor antagonist. Eplerenone is more selective for the aldosterone receptor, which generally results in fewer endocrine side effects such as gynecomastia, but both drugs share similar efficacy in lowering blood pressure and managing heart‑failure symptoms.

Inspra should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Inspra is taken orally, usually with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a prescriber.

The most serious risks include severe hyperkalemia, which can cause cardiac arrhythmias, and acute renal impairment. Patients should be monitored for signs of elevated potassium, such as muscle weakness or irregular heartbeat, and for any sudden decline in kidney function.

Eplerenone is contraindicated in individuals with known hypersensitivity to the drug, those with severe renal impairment, and patients with hyperkalemia (serum potassium >5.0 mmol/L). It should also be avoided in patients taking other potent potassium‑sparing agents without close medical supervision.